{"disease":{"id":"leukemia-chronic-lymphatic","name":"leukemia chronic lymphatic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04407845","title":"Atrial Fibrillation in Patients Receiving Ibrutinib","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"European Georges Pompidou Hospital","has_results":false},{"nct_id":"NCT02802943","title":"iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT07020533","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06508775","title":"Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT03204188","title":"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}